A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors
Rikke Løvendahl Eefsen, Jan Stenvang, Jiri Bartek, Per Pfeiffer, Line Tarpgaard, Susann Theile, Nils Brünner, Dorte L. Nielsen
Springer Nature ·
2026-02-16
· DOI 10.1186/s12885-026-15743-7
The publisher did not provide an abstract — full text is available via the link below.
Rikke Løvendahl Eefsen, Jan Stenvang, Jiri Bartek, Per Pfeiffer, Line Tarpgaard, Susann Theile et al. A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors. // BMC Cancer. – 2026. – DOI: 10.1186/s12885-026-15743-7. – URL: https://doi.org/10.1186/s12885-026-15743-7
Rikke Løvendahl Eefsen, Jan Stenvang, Jiri Bartek, Per Pfeiffer, Line Tarpgaard, Susann Theile, Nils Brünner, & Dorte L. Nielsen (2026). A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors. BMC Cancer. https://doi.org/10.1186/s12885-026-15743-7
Rikke Løvendahl Eefsen, et al. “A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors.” BMC Cancer, 2026. doi:10.1186/s12885-026-15743-7.
@article{Eefsen2026,
title = {A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors},
author = {Eefsen, Rikke Løvendahl and Stenvang, Jan and Bartek, Jiri and Pfeiffer, Per and Tarpgaard, Line and Theile, Susann and Brünner, Nils and Nielsen, Dorte L.},
journal = {BMC Cancer},
year = {2026},
doi = {10.1186/s12885-026-15743-7},
url = {https://doi.org/10.1186/s12885-026-15743-7}
}